Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Novonesis (Novozymes) B's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Novonesis (Novozymes) B's highest Yield on Cost was 3.29. The lowest was 0.00. And the median was 1.63.
MEX:NSISN's 5-Year Yield-on-Cost % is not ranked *
in the Chemicals industry.
Industry Median: 1.8 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Novonesis (Novozymes) B (MEX:NSISN) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Novonesis (Novozymes) B 5-Year Yield-on-Cost % Related Terms
MEX:NSISN vs LIN, SHW, ECL: 5-Year Yield-on-Cost % Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B 5-Year Yield-on-Cost % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's 5-Year Yield-on-Cost % falls into.
Novonesis (Novozymes) B 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Novonesis (Novozymes) B (MEX:NSISN) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Novonesis (Novozymes) B and its competitors. According to the industry distribution chart, Novonesis (Novozymes) B ranks #529 out of 1030 companies in the Chemicals industry, placing it in the top 51.4%.
Is Novonesis (Novozymes) B's 5-Year Yield-on-Cost % too high?
Novonesis (Novozymes) B's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Novonesis (Novozymes) B ranks #529 out of 1030 companies in the Chemicals industry, which is below the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's 5-Year Yield-on-Cost % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #529 out of 1030 companies for 5-Year Yield-on-Cost %. This places Novonesis (Novozymes) B in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Chemicals company?
The median 5-Year Yield-on-Cost % among Chemicals companies is 1.80, based on 1,030 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median 5-Year Yield-on-Cost % is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is MXN936.38, compared to a current price of MXN911.11 — trading 2.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Novonesis (Novozymes) B's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of MXN911.11 is trading 2.7% below its estimated GF Value™ of MXN936.38.
Key valuation signals for MEX:NSISN:
5-Year Yield-on-Cost %: 0.00
GF Value™: MXN936.38 vs. price of MXN911.11 (2.7% below fair value)
No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
95GF Score
Get the complete analysis for MEX:NSISN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NSISN has been successfully added to your 
